News
Sage Therapeutics appoints investor Jessica Federer to board of directors
Federer’s work focuses on addressing the gender gap in healthcare and innovation

The US biotech company Sage Therapeutics has announced the appointment of investor Jessica Federer to the company’s board of directors.
Federer, a managing partner at Supernode Ventures, aims to address a critical gap in innovation by accelerating change through investment in early-stage femtech and health technology companies.
She was the first chief digital officer for the Bayer AG group, as well as the first woman to hold that role in the industry.
During her tenure, Federer united the company’s global digital strategy and investments to accelerate growth and held leadership positions in regulatory affairs, market access, communications, and public affairs.
“I’m honoured to join the Sage Board of Directors at such an incredibly exciting time,” the investor said in a statement.
“Sage has led the way in maternal mental health care, an area of great need and one that is particularly important to me.
“I’m looking forward to supporting the company’s goal of redefining how we think about and treat a wide range of brain health conditions. I see the vast potential for data and digital strategies in the brain health area.”
Sage Therapeutics is a Massachusetts-based biotech developing brain health medicines.
The company aims to improve brain health and change how brain disorders are thought about and treated.
Barry Greene, Sage Therapeutics CEO, said: “We are thrilled to have Jessica join our board of directors.
“She is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry.
“Jessica’s innate curiosity, commitment to challenging convention, and patient-first mindset are consistent with the critical values that define our leaders.
“Her unique expertise in data and digitalisation at the intersection of policy and science will help us continue to scale our commercial growth ambitions.”
Federer began her public health career as an analyst at the Agency for Healthcare Research and Quality in the U.S. Department of Health and Human Services.
She has served on the United Nations International Telecommunications Union (UN-ITU) advisory board, as well as participated in engagements with the World Economic Forum, and is considered a thought leader in digital health.
Pregnancy
Climbing during pregnancy may be safer than long assumed, study finds

Climbing during the third trimester was not linked to higher rates of self-reported pregnancy complications in a global study.
The findings provide direct evidence on an activity pregnant women have traditionally been advised to avoid because of concerns about falls.
Researchers surveyed 692 people about climbing during pregnancy, falls, maternal and baby health outcomes and their return to the activity after giving birth.
The study recorded almost 64,000 hours of climbing among participants.
During that time, participants reported 155 “hard falls”, defined as falls or catches forceful enough to be remembered or cause concern.
The rate of adverse clinical events, meaning negative medical outcomes affecting the pregnancy or baby, was 0.03 per 1,000 hours of climbing exposure. All babies in the study were born live.
Researchers found no significant difference in pregnancy or foetal health outcomes between participants who stopped climbing at or before 27 weeks and those who continued beyond that point.
The findings suggest continuing the activity into the third trimester was not associated with increased self-reported complications among those surveyed.
The survey also found 96 per cent of participants said that, despite concerns about climbing while pregnant, they felt “happy” or “very happy” that they had continued.
Margie Davenport, professor in the Faculty of Kinesiology, Sport, and Recreation and lead author of the study, said the preliminary findings challenge an assumption about maternal exercise that had been based on opinion rather than research.
She said: “For decades we have restricted pregnant women from activities like climbing due to concern for their health and the health of the baby, but our evidence suggests it’s beneficial for both mental and physical health.”
Entrepreneur
Peripear wins Innovate UK Women in Innovation Award

Medtech startup Peripear has won an Innovate UK award for developing a wearable designed to prevent perineal trauma during childbirth.
The Oxford-based company is developing a hands-free warm compress device for use on the perineum during the second stage of labour.
Peripear describes its product as the world’s first automated perineal thermotherapy wearable, designed to prevent perineal trauma during childbirth.
The device is intended to reduce severe tearing and episiotomies while improving maternal comfort.
Peripear has secured an Innovate UK Women in Innovation Award and a £74,974 grant.
The funding will support further product development ahead of the company’s planned first-in-human study.
Nina van Schaick, co-founder and chief operating officer of Peripear and midwife, said: “I’m sure I wasn’t the only one to see this gap.
“I was incredibly lucky to meet my co-founder, Eviatar Natan, right as my frustration about the lack of translation of evidence into practice had peaked.
“There was a proven mechanism that could reduce injuries occurring in up to 90 per cent of vaginal births, and it was being left out of clinical pathways simply because no standardised tool existed to deliver it.
“I’m a farmer’s granddaughter, and when I started practising over 14 years ago, I asked: where is the tool I need to implement this evidence? I looked around and realised we were still asking clinicians to improvise.
“Peripear is what happens when the person who has lived the problem, both personally and professionally, meets the person who can help her build the solution.”
Hormonal health
Coffee linked to healthier body composition and distinct sex hormone changes – study

Higher coffee consumption has been linked to lower body fat, greater muscle mass and differing sex hormone patterns in men and women in a Finnish study.
Researchers found people who drank more coffee had lower levels of total and visceral fat, the fat stored around internal organs, as well as greater skeletal muscle mass.
These associations were seen even though participants had a similar body mass index (BMI), a measure of weight relative to height.
The University of Oulu study analysed data from 2,264 people aged 46 who were part of the Northern Finland Birth Cohort 1966, looking at habitual consumption alongside circulating metabolites, cardiometabolic risk markers and sex hormones.
In both men and women, higher consumption was correlated with lower circulating levels of branched-chain amino acids.
Persistently high levels of these molecules have previously been linked to insulin resistance, when the body responds less effectively to insulin, and a higher risk of type 2 diabetes.
The strongest differences between the sexes were seen in men. Higher consumption was linked to a more favourable glucose and insulin profile, higher total and bioavailable testosterone and increased levels of sex hormone-binding globulin (SHBG).
SHBG is a protein that carries sex hormones such as testosterone through the bloodstream and influences how much hormone is available for the body to use.
At the same time, free testosterone and the free androgen index were modestly lower in men.
Among women, hormone associations were more limited, mainly involving higher SHBG and lower measures of free androgens, a group of hormones that includes testosterone.
Luca Verroest, lead author of the study and doctoral researcher at the University of Oulu, said: “Coffee is consumed by millions of people every day, yet we still know surprisingly little about how it relates to our metabolism and hormones.
“What stood out in our findings was a distinct hormonal signature that didn’t disappear even after we took into account BMI and lifestyle factors, with several of these associations differing between men and women.”
The researchers said hormonal pathways could partly explain the relationship between consumption and metabolic health.
However, the research was observational, meaning it can identify associations but cannot establish that drinking coffee caused the biological differences seen among participants.
The study is particularly relevant in Finland, one of the world’s highest coffee-consuming countries, where annual consumption averages around 11.8 kilograms per person.
Researchers are now investigating whether coffee itself drives the biological changes and which compounds could be responsible, initially using animal models.
The longer-term aim is to move to human intervention studies, although the researchers said further research would be needed before the findings could be used to inform dietary recommendations.
News2 weeks agoUK femtech investment surges 194% in a decade, research finds
Entrepreneur2 weeks agoTidalSense raises £14m to expand five-minute COPD test across NHS
News2 weeks agoCross-Border Impact Ventures raises US$58m for women and children’s health
Wellness2 weeks agoCancer patient receives ‘landmark’ treatment in world-first
Insight2 weeks agoWomen urged to be wary of menopause misinformation on social media
Menopause2 weeks agoCultural stigma is a barrier to menopause help, black women say
Entrepreneur6 days agoApplications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase
Menopause6 days agoThird of women unaware of perimenopause mental health impact











